Day: March 17, 2026

PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer’s & Parkinson’s Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis focuses on Zervimesine’s treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB. “In the Phase 2 ‘SHIMMER’ study, we saw a treatment effect across neuropsychiatric, cognitive, motor, and global function domains with zervimesine treatment compared to placebo,” explained Anthony...

Conference Call to Be Held on April 16, 2026 at 2:00pm ET NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced that it will release its earnings for the first quarter of 2026 on Wednesday, April 15, 2026 after market close. The Company’s executive management team, led by Marc Holliday, Chairman and Chief Executive Officer, will host a conference call and audio webcast on Thursday, April 16, 2026 at 2:00pm ET to discuss the financial results. Simultaneous with the earnings release, supplemental data will be made available in the Investors section of the SL Green Realty Corp. website at https://slgreen.com under “Financial Reports”. The live conference call will be webcast in listen-only mode and a replay will be available in the Investors section...

Gateway Deployment Strengthens Security Upgrade Initiative – Enabling More Efficient, Effective Screening Process TORONTO, March 17, 2026 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced its Xtract One Gateway (“Gateway”) system has been selected by Alabama’s Morgan County Schools (“MCS”) to strengthen security processes across its facilities. The 18-school district will initially deploy Gateway across its many high school campuses: Brewer High School, Falkville High School, Priceville High School, West Morgan High School, and Danville High School. After evaluating several weapons screening systems on the market, MCS ultimately selected Xtract One’s Gateway for its ability to enable streamlined entry and operational processes. With Gateway, MCS students,...

SAN JOSE, Calif., March 17, 2026 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (NASDAQ: POET), a leader in integrated photonics solutions for artificial intelligence networks, and Lessengers, a developer of advanced optical connectivity technologies, today announced the joint development of a 1.6T 2×DR4 optical transceiver module designed for next-generation AI clusters and hyperscale data center networks. The effort combines POET’s highly integrated optical engines, built on its Optical Interposer™ platform, with Lessengers’ Direct Optical Wiring (DOW) technology, creating a scalable architecture for high-density optical interconnects required by emerging AI infrastructure. The 1.6T 2×DR4 transceiver will utilize POET’s optical engines to integrate lasers, modulators, photodiodes,...

COLUMBIA, Md., March 17, 2026 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (“Rekor” or the “Company”), a leader in developing and implementing state-of-the-art roadway intelligence systems, today announced that it will report its annual financial results for the fiscal year ended December 31, 2025, on Tuesday, March 31, 2026, after market close. On the same day, the Company will host its earnings conference call at 4:30 p.m. Eastern Time to discuss financial and operating results. CONFERENCE CALL INFORMATION‍Any person interested in participating in the call should please dial in approximately 10 minutes before the start of the call using the following information:‍ North America: Participant Dial-In: 877-407-8037 / +1 201-689-8037‍ Click here for participant International Toll-Free access...

New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Parkinson’s model of combined alpha-synuclein pathology and noradrenergic degeneration NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced new data of blarcamesine in a new Parkinson’s model of combined alpha-synuclein pathology and noradrenergic degeneration. Significant...

– First ZEVASKYN® commercial patient treatment completed in December – – ZEVASKYN launch momentum building in first quarter 2026 – – $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 – CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2025 and recent operational progress. “2026 is about building a steady cadence of biopsies and treatments,” said Vish Seshadri, Chief Executive Officer of Abeona. “We are focused on ensuring every ZEVASKYN patient has a seamless experience throughout their treatment journey. Establishing these commercial foundations will position us to scale-up ZEVASKYN in 2026 and beyond.” ZEVASKYN (prademagene zamikeracel) updatesFirst ZEVASKYN commercial patient...

MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., have submitted a supplemental application to ANMAT, the Argentinian health regulatory agency, and COFEPRIS, the Mexican health regulatory agency, respectively, seeking approval for an additional indication for MINJUVI® (tafasitamab), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1–3a) after at least one prior line of systemic therapy. Knight entered into an exclusive supply and distribution agreement with Incyte (NASDAQ: INCY) in September...

MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda. has received approval from ANVISA, the Brazilian health regulatory agency, for an additional indication for MINJUVI® (tafasitamab). The approval follows a supplemental regulatory filing and review by ANVISA under Project Orbis for MINJUVI®, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). 1 The approval is supported by data from clinical studies evaluating MINJUVI® in combination with rituximab and lenalidomide (R2), which demonstrated meaningful response rates and durable disease control in patients with previously treated...